...
机译:通过协同抗溶酶体酸化和快速药物释放来靶向癌基因KRAS突变体胰腺癌
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Univ Texas Southwestern Med Ctr Dallas Dept Pharmacol Simmons Comprehens Canc Ctr Dallas TX 75390 USA;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Univ Texas Southwestern Med Ctr Dallas Dept Pharmacol Simmons Comprehens Canc Ctr Dallas TX 75390 USA;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing 100084 Peoples R China;
Tsinghua Univ Sch Pharmaceut Sci Beijing 100084 Peoples R China;
Univ Texas Southwestern Med Ctr Dallas Dept Pharmacol Simmons Comprehens Canc Ctr Dallas TX 75390 USA;
Tsinghua Univ Sch Pharmaceut Sci Beijing Adv Innovat Ctr Struct Biol Beijing 100084 Peoples R China;
mutant KRAS; pancreatic cancer; lysosomal buffering; ultra-pH-sensitive micelles; drug delivery;
机译:通过协同抗溶酶体酸化和快速药物释放来靶向癌基因KRAS突变体胰腺癌
机译:通过以[〜(111)In] DOTA_nt-聚(二酰胺基丙烷)〜m-KRAS2 PNA-D(Cys-Ser-Lys-Cys)纳米粒子为靶点的突变KRAS2 mRNA成像人胰腺癌异种移植物。
机译:通过用[111In] DOTAn-聚(二酰胺基丙酰基)m-KRAS2 PNA-d(Cys-Ser-Lys-Cys)纳米粒子靶向突变的KRAS2 mRNA来成像人胰腺癌异种移植物。
机译:L-抗坏血酸可以消除突变克拉斯在人结肠癌细胞中介导的X基因依赖性的辛酸抗性
机译:针对胰腺癌中的突变KRAS。
机译:突变KRAS是胰腺癌的可治疗靶标
机译:通过将突变体KRAS2 mRNA与111IN dotan-poly(二亚硅烷酰基)M-KRAS2 PNA-D(Cys-Ser-Lys-Cys)纳米粒子靶向人胰腺癌异种移植物
机译:在体内shRNa-药物筛选中鉴定用于KRas突变癌症的新型靶向治疗组合。